Core Insights - Daré Bioscience, Inc. is advancing multiple innovative treatments for women's health, including a pivotal Phase 3 study for Ovaprene®, a hormone-free contraceptive, and a planned Phase 3 study for Sildenafil Cream to treat female sexual arousal disorder [1][3][9] Development Programs and Milestones - Ovaprene® is undergoing a pivotal Phase 3 efficacy study across the U.S., with a foundation grant of approximately $10.7 million to expand clinical sites and accelerate development [1][8] - Sildenafil Cream, a topical formulation for female sexual arousal disorder, is progressing towards a Phase 3 study, with ongoing discussions with the FDA regarding study design and endpoints [1][10] - DARE-HPV, a treatment for HPV-related cervical diseases, is preparing for a Phase 2 clinical study, supported by a $10 million award from ARPA-H [1][3] - DARE-VVA1, a tamoxifen formulation for dyspareunia, is in preparation for a Phase 2 study, while DARE-PTB1, an intravaginal ring for preterm birth prevention, is preparing for a Phase 1 study with a $2 million grant from NICHD [1][4] Financial Performance - For the quarter ended September 30, 2024, the company reported cash and cash equivalents of $11.2 million, with a net loss of $4.7 million compared to a loss of $8.3 million in the same quarter of 2023 [11][28] - Research and development expenses decreased by 60% to $2.7 million, primarily due to the completion of the Phase 2b study for Sildenafil Cream [13][28] - General and administrative expenses were $2.0 million, down from $2.7 million in the previous year, reflecting reduced professional services and commercial readiness expenses [12][28] Strategic Collaborations and Funding - The company has established a $15 million equity line arrangement with Lincoln Park Capital Fund and secured $22 million in non-dilutive strategic royalty financing, positioning it for significant milestones in 2025 [5][11] - The collaboration with Bayer HealthCare for Ovaprene® is expected to enhance market opportunities, as there are currently no FDA-approved monthly hormone-free contraceptives [6][7]

Dare Bioscience, Inc. (DARE) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years ...

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 14, 2024, to review its financial results for the quarter ended September 30, 2024 and to provide a company update. The company will release its financial results after the close of market on Thursday, November 14, 2024, and prior to the conference call and webcast. To acc ...

DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management. Essentially all cervical cancer cases worldwide are caused by HPV infection. SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) --  Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an  ...

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced it entered into a $15 million common stock purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. Under the terms and conditions of the purchase agreement, Daré will have the right, from time to time and at its sole discretion, to sell up to $15 million of its stock ...

Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2024 Earnings Call Transcript August 12, 2024 4:30 PM ET Company Participants MarDee Haring-Layton - CAO Sabrina Martucci Johnson - President and CEO Conference Call Participants Catherine Novack - Jones Research Douglas Tsao - H.C. Wainwright & Co. Operator Welcome to the conference call hosted by Daré Bioscience to review the company's second quarter financial results and to provide a general business update. This call is being recorded. My name is Leonardo, and I wi ...

Dare Bioscience, Inc. (DARE) came out with quarterly earnings of $1.52 per share, beating the Zacks Consensus Estimate of a loss of $0.57 per share. This compares to loss of $1.20 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 366.67%. A quarter ago, it was expected that this company would post a loss of $0.72 per share when it actually produced a loss of $0.84, delivering a surprise of -16.67%. Over the last four quarters, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36395 DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorp ...

Exhibit 99.1 Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones ● Ovaprenehormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United States ● Sildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder continued operational progress t ...

Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United States Sildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder continued operational progress toward a planned Phase 3 study; additional FDA feedback forthcoming; Phase 3 design, development, and coll ...